Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

Detalles Bibliográficos
Autores principales: Evans, Marc, Dejager, Sylvie, Schweizer, Anja, Foley, James E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374076/
https://www.ncbi.nlm.nih.gov/pubmed/25783754
http://dx.doi.org/10.1007/s13300-015-0104-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374076/
https://www.ncbi.nlm.nih.gov/pubmed/25783754
http://dx.doi.org/10.1007/s13300-015-0104-4

Ejemplares similares